<DOC>
	<DOCNO>NCT01747174</DOCNO>
	<brief_summary>The purpose study determine whether intra-coronary adenosine sodium nitroprusside ( SNP ) deliver selectively via thrombus aspiration catheter ( unsuccessful via coronary microcatheter ) follow thrombus aspiration Primary Percutaneous Coronary Intervention ( P-PCI ) reduce microvascular obstruction ( MVO ) parameter infarct size measure cardiac MRI , compare standard treatment follow thrombus aspiration patient present ST-elevation myocardial infarction ( STEMI ) .</brief_summary>
	<brief_title>REperfusion Facilitated LOcal Adjunctive Therapy ST-elevation Myocardial Infarction</brief_title>
	<detailed_description>&gt; 100,000 patient suffer STEMI present UK year . P-PCI UK increase exponentially . In 2004 &lt; 1500 P-PCI 2007 2008 figure increase 5902 9224 respectively ( BCIS database ) . Although P-PCI deliver quickly effective thrombolysis , efficacy , essentially mechanical , technique limit unpredictable phenomenon no-reflow under-stated lesser degree MVO . As UK centre adopt P-PCI dilemma attenuate MVO remain . Currently consensus optimal management prevent attenuate MVO particularly thrombus laden lesion treat P-PCI . There divergent clinical practice , even within institution , UK worldwide . This solid evidence base inform clinician . The current option interventional cardiologist : 1 . Routinely aspirate thrombus give IC vasodilator intervention high burden thrombus formation lesion . 2 . Perform standard P-PCI give IV vasodilator angiographic no-reflow develops . 3 . Routinely consider angiographically silent MVO ( i.e grade true `` no-reflow '' ) may important impact infarct size clinical outcome treat prophylactically . Few clinician follow think . Indeed , appear impossible predict incidence ( no-reflow/MVO ) present angiogram ( pre- post- wire balloon ) argue irrespective thrombus burden would better undertake prophylactic treatment patient , follow use aspiration catheter , delivery agent able , theory least , reduce ( angiographically undetectable ) MVO . Several study IC adenosine SNP show favourable effect attenuate MVO . However , size effect either drug whether indeed difference reduce MVO infarct size undetermined . The objective propose study determine : 1 . Whether adjunctive pharmaco-therapy time P-PCI follow thrombus aspiration , reduce CMR-determined MVO infarct size . 2 . Whether difference adenosine SNP reduce CMR-detected MVO infarct size , give selectively distally via thrombus aspiration catheter coronary microcatheter . 3 . The correlation angiographic , include recently design computer-assisted myocardial blush quantification 'Quantitative Blush Evaluator ' ( QuBE ) , myocardial perfusion marker , CMR detect MVO infarct size , well clinical outcome ( MACE ) 30 day .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Nitroprusside</mesh_term>
	<criteria>≥ 18 year age . Informed ASSENT ( verbal consent ) prior angiography . STEMI ≤ 6 hr symptom onset , require primary reperfusion PCI . Singlevessel coronary artery disease ( non culprit disease ≤70 % stenosis angiography ) TIMI flow 0/I angiography . Contraindications : PPCI * , CMR** , contrast agent , study medication : Adenosine*** , SNP**** , Aspirin , Thienopyridine Bivalirudin . SBP ≤ 90mmHg Cardiogenic Shock Previous Q wave myocardial infarction Culprit lesion identify located bypass graft Stent thrombosis . Left main disease . Known severe asthma . Known stage 4 5 chronic kidney disease ( eGFR &lt; 30ml/min ) . Pregnancy . Notes : * Exclusion criterion PPCI ( presentation timing , inadequate arterial access etc ) ; patient unable tolerate `` prolonged '' PCI procedure ( operator ' opinion ) . ** Absolute contraindication CMR ( Pacemaker , ICD , intracranial metal clip ) . *** Contraindications Adenosine ( know hypersensitivity Adenosine , sick sinus syndrome , second third degree atrioventricular block except patient function artificial pacemaker , long QT syndrome define QTc &gt; 450 m baseline ) . ECG undertaken first dose study drug QT/QTc record compare baseline . If QTc record first dose study drug exceed 450ms increase QT/QTc &gt; 60 m baseline , second dose abandon record . **** Contraindications SNP ( know hypersensitivity SNP , compensatory hypertension may see arteriovenous shunt coarctation aorta , high output failure , congenital optic atrophy tobacco amblyopia ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>STEMI</keyword>
	<keyword>Microvascular Obstruction</keyword>
	<keyword>No-reflow</keyword>
	<keyword>Adenosine</keyword>
	<keyword>Sodium Nitroprusside</keyword>
</DOC>